Insmed Incorporated (INSM)

NMS – Real Time Price. Currency in USD

103.38

-1.09 (-1.04%)

At close: Jun 26, 2026, 4:00 PM EDT

103.99

+0.61 (0.59%)

After-hours: Jun 26, 2026, 7:56 PM EDT

09.06.2026

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.

27.05.2026

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.

20.05.2026

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

18.05.2026

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.

12.05.2026

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

08.05.2026

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

06.05.2026

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis Symptoms Often Overlap with COPD or Asthma and May Go Unrecognized for Years, Highlighting the Need to Look Deeper at Respiratory Symptoms — — TV Personality, Ty Pennington, Brings Visibility to the Chronic Lung Condition Through His Experience Caring for His Mother, Who is Living with Bronchiectasis — BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced a collaboration with Emmy® Award–winning TV host, designer, and carpenter, Ty Pennington, to launch Suspect Bronchiectasis (Suspect BE).

07.04.2026

Insmed Provides Clinical Update on Phase 2b CEDAR Study

—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.

Insmed Incorporated (INSM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Insmed Incorporated (INSM)

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Videos

Press releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Videos

Press releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Search stocks

Insmed Incorporated (INSM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Insmed Incorporated (INSM)

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Videos

Press releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Videos

Press releases

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study